On January 19, 2026, Huadong Medicine (000963.SZ) issued an official announcement,Zhejiang Doer Biologics Co., Ltd., a subsidiary independently developed by Huadong Medicine Co., Ltd.FICFirst-in-class long-acting tri-agonist DR10624 targeting FGF21R/GCGR/GLP-1RFor "Treating Metabolic Associated Fatty Liver Disease/Metabolic Associated Fatty Liver Disease"ThePhase II ClinicalCompletedAll subjects enrolled.
It is reported that,DR10624, as a self-developed product by Doer Biologics,World's first targeted FGF21R, GCGR, GLP-1RThe long-acting tri-specific agonist. The DR10624-202 study enrolled its first participant in April 2025; meanwhile, DR10624 is used forTreatmentMASLD's clinical trial in the United States was approved by the FDA in January 2026.。Huadong Medicine has implemented a differentiated layout in the hypoglycemic/weight loss field around the GLP-1R target, constructing an array includingOral, InjectableIncluding long-acting and multi-target global innovative drugs and biosimilars combinedComprehensive Product Pipeline, including liraglutide injection, which is the first GLP-1R product in China approved for obesity or overweight indications. Other products under development also includeOral small molecule GLP-1R agonist HDM1002, dual-target agonist HDM1005 and SCO-094, long-acting triple-target agonist DR10624, TTP273, biosimilar semaglutide injectionAnd many other products.
Huadong Medicine (000963.SZ) has been deeply engaged in the medical aesthetics sector for nearly 10 years. Since 2018, it has continuously introduced high-quality medical aesthetic products from home and abroad through investment and mergers and acquisitions. Up to now, Huadong Medicine's global medical aesthetics business has acquired36 Products in the Non-invasive + Minimally Invasive Medical Aesthetics FieldAmong them, 22 products have been launched in China and overseas, and 14 globally innovative products are under development. The product portfolio covers mainstream non-surgical medical beauty fields such as facial fillers, facial cleansing, and thread embedding.
In 2013, Huadong Ningbo introducedHyaluronic Acid by LG Corporation of KoreaThe product Yiwon became one of the earlier companies in the industry to adopt the license-in model, achieving a single-product revenue of 600-700 million yuan in 2018-2019, and emerging as the leading player in the highly competitive hyaluronic acid market.In 2018, the companyAcquisition of UK Sinclair, and obtained the blockbuster product "Ellansé®" (also known as "Young Girl Needle"); On April 13, 2021, Ellansé® S-type was approved for marketing by the National Medical Products Administration; On January 3, 2023, Ellansé® M-type successfully completed the enrollment and clinical injection of the first subject in the China clinical trial; On March 23, 2023, Ellansé® M-type successfully completed the enrollment of all subjects in the China clinical trial.In 2019, the companyReached a cooperation agreement with U.S. R2 company and holds 26.6% shares.%, obtaining the rights to R2 Company's Fo and F1/2 products in the Asia-Pacific region. The R2 team possesses top-tier R&D capabilities, with its core member, Professor Anderson, having previously sold his developed product CoolSculpting to Allergan for 16 billion yuan.In August 2020, Huadong Medicine andSouth Korean listed company JetemaSign a strategic cooperation agreement to obtain itsExclusive Agency Rights for Botulinum Toxin Type A Products in ChinaJetema applied for the IND of its Type A botulinum toxin product in China in 2021, with an expected approval for market launch in 2024.In March 2021, the wholly-owned subsidiary Sinclair acquiredSpanish Medical Aesthetics Device Company HighTechThe main products already on the market include Cooltech, Cooltech Define, Crystile and other cryolipolysis series, as well as Primelase, Elysion and other laser hair removal series.September 2021,Huadong Medicine Co., Ltd. Reaches Cooperation with Belgian KiOmed Company, Obtained the exclusive license for the global (excluding the United States) dermatological aesthetic field for its four innovative KiOmedine chitosan medical beauty products under research, which is expected to further enhance the hyaluronic acid product portfolio.In February 2022, the wholly-owned subsidiary SinclairAcquisition of Medical Aesthetics Device Company VioraThe company's main listed products include the Reaction multi-frequency radiofrequency device, the V series multi-energy platform (radiofrequency, intense pulsed light, laser) multifunctional operating platform, the EnerJet needle-free minimally invasive high-pressure jet device, and the Pristine "diamond microcrystal dermabrasion device," among others. The Reaction product has obtained China's Class III medical device registration certificate and is expected to be quickly launched into the market.In September 2022, a new high-end hyaluronic acid filler containing lidocaine from Sinclair, a wholly-owned subsidiaryMaiLi ExtremeThe first subject in China has been successfully enrolled and received clinical injection at the Ninth People's Hospital affiliated to Shanghai Jiaotong University School of Medicine. MaiLi Hyaluronic Acid product obtained the EU CE certification in June 2020 and was launched in the European market in the first half of 2021.
On December 26, 2022, Sinclair, a wholly-owned subsidiary in the UK,Regenerative Medical Aesthetics Injectable Lanluma® Type V and Type XApproved by the Hainan Provincial Drug Administration for clinical urgent need, it is permitted as an imported medical device to be used by designated doctors in the Medical Aesthetics Department of Huahan (Hainan) Cosmetic Surgery Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. It is intended for increasing the volume of facial and body depressions, particularly suitable for correcting skin depressions.
It is reported that Lanluma® is currently the only product approved globally.Can be used for buttock and thigh augmentationThe regenerative product. According to Huadong Medicine, Lanluma® comes in two different specifications: Type V and Type X. Type V is used for filling smaller areas such as the face, upper arms, neck, and décolleté triangle area, while Type X is used for larger areas like the buttocks. Its main component is poly-L-lactic acid (PLLA), which is also known as the "baby face needle" in China.On July 4, 2023, Huadong Medicine Co., Ltd., a wholly-owned subsidiary of Huadong Medicine, submittedLiraglutide Injection for Obesity or Overweight IndicationsThe marketing authorization application has been approved, with the trade name Lirupin®, in the specification of 3ml:18mg (prefilled injection pen + cartridge), making it the first company in China to obtain an approval for a "weight loss" indication in the GLP-1 inhibitor field.On October 17, 2023, Huadong Medicine's wholly-owned Hong Kong subsidiary signed an exclusive product licensing agreement with South Korea's ATGC Co., Ltd., obtaining ATGC's containingATGC-11 Injection of Botulinum Toxin Type AGlobal exclusive license (excluding India) in regions including China, the United States, Europe, and non-exclusive license in South Korea, covering clinical development, registration, and commercialization rights for all indications in medical aesthetics and therapeutics.
On November 14, 2023, Huadong Medicine and Chongqing Yuyan announced the signing of an exclusive distribution agreement for the injectable recombinant botulinum toxin type A YY001.Huadong Medicine Obtains Ownership of Chongqing YuyanRecombinant Botulinum Toxin Type A YY001Exclusive commercial rights in the medical aesthetics indications field in mainland China, Hong Kong Special Administrative Region, and Macao Special Administrative Region.It is reported that YY001 is the first recombinant Type A botulinum toxin candidate product in China approved for clinical trials, and it is also the only recombinant Type A botulinum toxin candidate product globally currently in clinical stage.
On February 20, 2024, Huadong Medicine Co., Ltd. issued an announcement,The marketing application for ATGC-110, the Type A botulinum toxin under South Korea's ATGC company exclusively represented by the company, has been accepted by South Korea’s Ministry of Food and Drug Safety (MFDS).. It is reported that,ATGC-110 is a neuroregulatory substance independently developed by ATGC, with its active pharmaceutical ingredient being 150kDa Type A botulinum toxin, used to improve symptoms in adult patients.Moderate to Severe Glabellar Lines。
February 29, 2024Huadong MedicineMaiLi, a hyaluronic acid sodium injection containing lidocaine from Sinclair, a wholly-owned subsidiary in the UK®Extreme Achieves Primary Endpoint in Clinical Trials in China, This clinical study mainly focuses on evaluating MaiLi®Extreme: Efficacy and Safety of Injection in the Supraperiosteal Plane and/or Subcutaneous Adipose Tissue of the Face for Correcting Mild to Moderate Chin Retrusion
On March 11, 2024, HDM1005 Injection, filed by Sinopharm Huadong (a subsidiary of Huadong Medicine), received clinical trial implied permission.The indications are weight management for overweight or obese populations and type 2 diabetes. It is reported that HDM1005, a long-acting dual agonist peptide targeting GLP-1R/GIPR, was officially submitted for clinical trials on December 23, 2023.
On April 3, 2024, the official website of the Center for Drug Evaluation of the National Medical Products Administration showed that the marketing application for the semaglutide injection "Jiutai" submitted by Hangzhou Jiuyuan Gene, a subsidiary of Huadong Medicine, has been accepted., Indications: Type 2 Diabetes. According to reports,Jiuyuan Gene submitted"Ji You Tai"YesThe first semaglutide biosimilar in China.
On May 9, 2024, Xinkeli Aesthetics, a wholly-owned subsidiary of Huadong Medicine Co., Ltd.SinclairThe National Operation Conference of REACTION by Huadong Medicine and the Launch Event of Rui·Slimming Project Successfully Held at Conrad Hangzhou.It is reported that with the release of REACTION芮艾瑅's new body treatment head, the application scenarios of radiofrequency treatment have been extended from the face to the entire body, bringing new and personalized solutions to the field of body contouring.
On June 19, 2024, Sinclair, a wholly-owned subsidiary of Huadong Medicine, will host the launch event for the second generation of Ellansé (Evanese) at the Shanghai Shangri-La Hotel under the theme "Scientific Haute Couture, Radiant Rebirth."It is reported that,The second-generation new products of Yiyan Shi consist of three products: Zhenyan (large microspheres), Zhizhen (medium microspheres), and Jingyan (medium microspheres). Based on three different sizes of microspheres, they can achieve "highly customized" effects in different dimensions, addressing the needs of users of different age groups from various dimensions.。
On July 14, 2024, KIO015, an injectable skin filler product under Sinclair, a wholly-owned UK subsidiary of Huadong Medicine, submitted an application for EU CE certification.It is reported that the product is expected to obtain EU CE certification in 2025 and is likely to become the world's first non-animal-derived chitosan medical aesthetics filler.
September 13, 2024,Huadong Medicine's Participating Company, Chongqing Yuyan Pharmaceutical Co., Ltd., Announces Successful Completion of Phase III Clinical Study for Recombinant Botulinum Toxin Type A Injection YY001 in Treating Moderate to Severe Glabellar Lines.It is reported that YY001 is a product independently developed by Yuyan Pharmaceutical with global intellectual property rights, and Huadong Medicine has the exclusive commercial rights for medical aesthetics indications in mainland China, Hong Kong, and Macao.
September 11, 2024Huadong Medicine Issues Public AnnouncementWillInvestment of 202 million yuanExpansion of the "Comprehensive Peptide API Workshop" at Phase II Plant of Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd.。According to reports,After the completion of this project, it will be able to achieve an annual production of250kg of Semaglutide API, 120kg of Liraglutide Injection API, 80kg of Degludec Insulin API.
September 24, 2024,Under Huadong MedicineHuadong Medicine's "Intense Pulsed Light and Radio Frequency Therapy Device" V20 officially received approval from the National Medical Products Administration (NMPA).Registration Certificate No.: GJXZZJ 20243090527.It is reported that,V20 is asSinclair Wholly-Owned SubsidiaryVioraThe multi-functional medical aesthetic operation platform, which integrates radio frequency (RF) and intense pulsed light (IPL) energy sources, has obtained FDA approval in the United States and CE certification in the European Union.
On October 11, 2024, the clinical trial for the "Weight Management" indication of Semaglutide Injection jointly submitted by Huadong Medicine's wholly-owned subsidiaries, Sinopharm Huadong and Hangzhou Jiangdong, was approved by the National Medical Products Administration.It is reported that,Huadong Medicine and Chongqing Paikin have completed the enrollment of all subjects in the Phase III clinical study for the "diabetes" indication of the semaglutide injection. The primary endpoint data is expected to be obtained in Q4 2024.
On October 24, 2024, Huadong Medicine Co., Ltd. released its financial report for the first three quarters. The medical aesthetics sector achieved a revenue of 1.909 billion yuan in the first three quarters.An increase of 1.90% year-on-yearAmong them, international Sinclair achieved revenue of approximately 776 million RMB, a year-on-year decrease of 20.30%; domestic Xinkeli Aesthetics achieved operating revenue of 909 million RMB, a year-on-year increase of 10.31%.。
November 15, 2024, Huadong MedicineAnnounced externally, the companySignificant progress has been made in the domestic clinical trials of four medical beauty products under the company.It is reported that,Ellansé® Yiyanshi® S-type has completed the enrollment of all subjects in the new indication clinical trial; Lanluma® V has completed the enrollment of all subjects in the clinical trial, initiating the multi-center registration clinical research phase in China; KIO021 has completed the discussion meeting on the study protocol, and the clinical trial in China has been successfully launched; MaiLi® Precise has completed the primary endpoint follow-up for all subjects in the clinical trial in China.
January 20, 2025,"Cross-linked hyaluronic acid sodium gel injectable with lidocaine" distributed by Xinkeli Aesthetics Shanghai Company, a wholly-owned subsidiary of Huadong MedicineMaiLi®ExtremeOfficially approved by the National Medical Products Administration, Registration No.: GJXZJ20253130026.It is reported that,MaiLi®ExtremeIt is the one with the highest concentration of hyaluronic acid and the strongest fullness capacity among the four products, which can instantly fill and shape, and quickly improve chin retrusion after injection.
January 23, 2025,Huadong Medicine's wholly-owned subsidiary, Xinkeli Aesthetics, submitted the application for "The registration application for "Ellansé®伊妍仕®M Type" polycaprolactone microsphere facial filler has been officially accepted by the National Medical Products Administration.It is reported that,Yiyanshi® M-Type, compared to the S-Type, can induce long-term collagen regeneration with longer-lasting effects, offering excellent filling performance and safety.
March 5, 2025, Huadong MedicineWholly-owned subsidiaryViora's Class III medical device "Optical RF Therapy Device" V30 registration application has been officially accepted by the National Medical Products Administration (NMPA).It is reported that,V30 was developed by Viora, a wholly-owned subsidiary of Sinclair.Integrating RF, IPL, and Nd:YAG laser energy sourcesAn integrated multifunctional medical aesthetics operation platform, mainly used for skin tightening, hair removal, vascular and pigmented lesions, acne, etc.March 31, 2025Semaglutide Injection Submitted by Jiangdong Company, a Wholly-Owned Subsidiary of Huadong Medicine (Sino-American Huadong)The marketing authorization application for HDG1901 has been accepted, with the indication being "Type 2 Diabetes Mellitus."It is reported that,Semaglutide InjectionClinical trial application for the "Weight Management" indication was submitted onApproved on October 11, 2024.April 17, 2025Huadong Medicine's subsidiary Hangzhou Zhongmei Huadong independently developed the innovative oral small molecule GLP-1 receptor agonist HDM1002 tablets for "weight loss indications," and the first subject was enrolled and dosed in the Phase III clinical trial at Yueyang People's Hospital.It is reported that this study is a multi-center, randomized, double-blind, placebo-controlled parallel trial.ⅢPhase clinical study to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adult subjects.On July 22, 2025, the clinical trial application for HDM1010 tablets submitted by Sinopharm Huadong (a wholly-owned subsidiary of Huadong Medicine Co., Ltd.) was officially approved by the U.S. FDA, with the indication being weight management for overweight or obese populations.It is reported that, as of now,HDM1010 tablets have been approved for 2 indications.FDA Approval, Including Type 2 Diabetes andWeight Management for Overweight or Obese Populations。
On August 19, 2025, Huadong Medicine released its half-year financial report. The company achieved a revenue of 21.675 billion yuan, representing a year-on-year increase of 3.39%; the net profit attributable to shareholders was 1.815 billion yuan, marking a year-on-year growth of 7.01%.It is reported that,H1 2025: Huadong Medicine's Medical Aesthetics Sector Achieves Total Revenue of 1.112 Billion YuanAmong them, the wholly-owned subsidiary, UK SinclairContributionRMB 5.24 billion, with RMB 5.43 billion contributed by Sinclare Aesthetics in China, representing a year-on-year decrease of 12.15%.
September 30, 2025, Huadong MedicineKIO021, a carboxymethyl chitosan solution under Sinclair, a wholly-owned subsidiary in the UK, completed the first subject injection in its China clinical study at Peking University First Hospital. The study aims to evaluate its efficacy and safety in improving facial skin condition.
On October 28, 2025, Huadong Medicine Co., Ltd. released its financial report for the first three quarters. The company achieved a revenue of 32.664 billion yuan, representing a year-on-year increase of 3.77%; net profit reached 2.748 billion yuan, marking a year-on-year growth of 7.24%.According to reports,In the first three quarters of 2025, the medical aesthetics sector achieved operating revenue of 1.568 billion yuan, representing a year-on-year increase of 113.7%. Of this, Sinclair abroad achieved operating revenue of 719 million yuan, while China's Sinclare Aesthetics achieved operating revenue of 745 million yuan.
On January 5, 2026, Huadong Medicine and MC2 announced the signing of a strategic cooperation agreement, under which Huadong Medicine obtained the dermatological skincare cream Biomee® from MC2.#1 and Biomee®#2 Cream in Greater ChinaExclusive Commercialization Rights。According to reports,The Biomee® series of products utilize MC2's PAD® technology, offering a safe, user-friendly, and functional solution for discomfort caused by dry skin.
